Sonnet Releases Virtual Investor “What This Means” Segment
(NASDAQ:SONN), – Dr. Richard Kenney, Chief Medical Officer of Sonnet, discusses the recently announced expansion of its clinical study of patients with platinum-resistant ovarian cancer (PROC) (SB221) – Watch the “What This Means” video here PRINCETON, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) — Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the “Company” or “Sonnet”), a clinical-stage company […]